Skip to main content
Fig. 2 | Journal of Pharmaceutical Health Care and Sciences

Fig. 2

From: Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study

Fig. 2

A) Change in Uβ2MG (median; IQR) over 288 weeks in HIV-positive individuals who switched from TDF to antiretroviral therapy including TAF and continued taking it. B) Change in Uβ2MG (median; IQR) over 288 weeks in each group classified by eGFR level at the time of switching from TDF to TAF (week 0, TAF0). In both (A) and (B), Wilcoxon signed rank test was performed at 48 weeks (TAF48), 96 weeks (TAF96), 144 weeks (TAF144), 192 weeks (TAF192), 240 weeks (TAF240), and 288 weeks (TAF288), using TAF0 as the reference, with a significance level of p < 0.05. The sample size of B) at each survey from TAF0 to TAF288 was 11 in group G1, 33 in group G2, and 7 in groups G3a, b

Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us